Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
A dedicated Phase 3 trial evaluating retatrutide specifically for metabolic dysfunction-associated steatotic liver disease is currently underway
Treatment of Obesity: Weight Loss and Bariatric Surgery
7782 Additionally, studies in healthy humans have shown GLP-1 infusion to increase sodium excretion by kidneys
Maintaining proper reconstitution and storage ensures you are getting the full dose you expect
Understanding your fasting glucose, HbA1c, lipid profile, liver function, kidney markers, and thyroid status helps providers detect which biomarkers may shift most dramatically on therapy
Unlike single-pathway incretin peptides, Retatrutide is researched for its interaction across GLP-1, GIP, and glucagon receptor systems
US$ 28.30
US$ 27.91
US$ 25.36
US$ 21.96
